ENGNW — enGene Holdings Inc. Warrants

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for ENGNW in the TickerWise workspace.

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: CA
• Exchange: NASDAQ
• Employees: 56
• Website: https://www.engene.com

Latest SEC filings for ENGNW

• 2026-08-14SCHEDULE 13G/A
• 2026-08-14SCHEDULE 13G/A
• 2026-08-14SCHEDULE 13G/A
• 2026-08-12SCHEDULE 13G/A
• 2026-07-22SCHEDULE 13G
• 2026-05-15SCHEDULE 13G/A
• 2026-05-14SCHEDULE 13G
• 2026-05-14SCHEDULE 13G/A
• 2026-05-08ARS
• 2026-03-09424B5

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.